Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cutaneous melanoma is the most serious skin malignancy and new therapeutic strategies are needed for advanced melanoma. TP53 mutations are rare in cutaneous melanoma and hence activation of wild-type p53 is a potential therapeutic strategy in cutaneous melanoma. Here, we investigated the WIP1 inhibitor, GSK2830371, and MDM2-p53 binding antagonists (nutlin-3, RG7388 and HDM201) alone and in combination treatment in cutaneous melanoma cell lines and explored the mechanistic basis of these responses in relation to the genotype and induced gene expression profile of the cells. METHODS: (WM164, WM35-R and CHL-1) melanoma cell lines were used. The effects of MDM2 and WIP1 inhibition were evaluated by growth inhibition and clonogenic assays, immunoblotting, qRT-PCR gene expression profiling and flow cytometry. RESULTS: melanoma cells, indicating the potentiation worked in a p53-dependent manner. The siRNA-mediated knockdown of p53 provided further evidence to support the p53 dependence. GSK2830371 increased p53 stabilisation through Ser15 phosphorylation and consequent Lys382 acetylation, and decreased ubiquitination and proteasome-dependent degradation when it was combined with MDM2 inhibitors. These changes were at least partly ATM mediated, shown by reversal with the ATM inhibitor (KU55933). GSK2830371 enhanced the induction of p53 transcriptional target genes, cell cycle arrest and apoptosis. CONCLUSIONS: GSK2830371, a WIP1 inhibitor, at doses with no growth-inhibitory activity alone, potentiated the growth-inhibitory and cytotoxic activity of MDM2 inhibitors by increasing phosphorylation, acetylation and stabilisation of p53 in cutaneous melanoma cells in a functional p53-dependent manner.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610
Kruse, J.-P., & Gu, W. (2009) · Cell · doi:10.1016/j.cell.2009.04.050 · Cited by 1,610 · cited 1×
“Post-translational modification of p53 has critical effects on its stability and function (Kruse and Gu, 2009).”
BackgroundAwakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881 · cited 1×
“This results in activation of the p53 pathway in p53WT (p53 wild type) rather than p53MUT (p53 mutated) cancer cells, causing cell cycle arrest, apoptosis and growth inhibition of human cancer cells (Brown et al, 2009).”
BackgroundDiscovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595 · cited 1×
“The RG7388 (Idasanutlin), an orally available second-generation MDM2–p53 binding antagonist, efficiently suppressed tumour growth in vivo (Ding et al, 2013); clinical trials of RG7388 are currently ongoing to investigate the clinical efficacy of MDM2 inhibitors in relapsed multiple myeloma…”
Acetylation of p53 inhibits its ubiquitination by Mdm2
Li, M., Luo, J., Brooks, C. L., & Gu, W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200578200 · Cited by 503
Dumaz, N., & Meek, D. W. (1999) · The EMBO Journal · doi:10.1093/emboj/18.24.7002 · Cited by 455
The p53 orchestra: Mdm2 and Mdmx set the tone
Wade, M., Wang, Y. V., & Wahl, G. M. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.01.009 · Cited by 450
MDM4 is a key therapeutic target in cutaneous melanoma
Gembarska, A., Luciani, F., Fedele, C., Russell, E. A., Dewaele, M., Villar, S., Zwolinska, A., Haupt, S., de Lange, J., Yip, D., et al. (2012) · Nature Medicine · doi:10.1038/nm.2863 · Cited by 327 · cited 1×
“…expressions of MDMX and WIP1 (Supplementary Figure S11) and showed there was no clear correlation between basal expression levels and responses to MDM2 and WIP1 inhibition, as MDM4 506 www.bjcancer.com | DOI:10.1038/bjc.2017.433 was overexpressed in B65% melanoma cases (Gembarska et al, 2012).”
BackgroundInfluentialA threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis.
Kracikova, M., Akiri, G., George, A., Sachidanandam, R., & Aaronson, S. A. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2012.155 · Cited by 261 · cited 1×
“…target genes responsible for cell cycle arrest and apoptosis, apoptosis has been reported only to proceed in certain conditions, such as achieving a transcriptional threshold by p53 reactivation or suppression of its negative regulators (Kracikova et al, 2013; Lu et al, 2013; Khoo et al, 2014).”
BackgroundCooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity
Sriraman, A., Radovanovic, M., Wienken, M., Najafova, Z., Li, Y., & Dobbelstein, M. (2016) · Oncotarget · doi:10.18632/oncotarget.9302 · Cited by 44 · cited 2×
“…studies have shown that GSK2830371 can enhance p53-mediated tumour suppression by MDM2 inhibitors, nutlin-3 (Esfandiari et al, 2016; Pechackova et al, 2016), nutlin-3a (Sriraman et al, 2016) and RG7388 (Esfandiari et al, 2016) or by chemotherapy (Gilmartin et al, 2014; Pechackova et al, 2016).”
BackgroundResult
Cited by
Hines, J., Lartigue, S., Dong, H., Qian, Y., & Crews, C. M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2918 · Cited by 348
“Nutlins were initially developed to act as a pharmacological means to elevate expression of the tumor suppressor p53 and there have been numerous reports (47-49) concerning the potential of nutlins as anti-cancer drugs/adjuvants.”
Kocik, J., Machula, M., Wisniewska, A., Surmiak, E., Holak, T. A., & Skalniak, L. (2019) · Cancers · doi:10.3390/cancers11071014 · Cited by 46
“the phosphorylated state of key proteins engaged in DNA damage response [15].”
BackgroundInfluential
Metadata
- Authors
- Wu, C.-E., Esfandiari, A., Ho, Y.-H., Wang, N., Mahdi, A. K., Aptullahoglu, E., Lovat, P., & Lunec, J.
- Venue
- British Journal of Cancer
- Published
- 2017-12-12
- Volume
- 118
- Issue
- 4
- Pages
- 495-508
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2775825721
- Cited by
- 61
- References
- 10
- FWCI
- 2.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.